Starpharma Holdings Limited
SPHRY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $7 |
| % Growth | -29.5% | 40.2% | -75.9% | – |
| Cost of Goods Sold | $2 | $5 | $5 | $1 |
| Gross Profit | -$1 | -$2 | -$3 | $6 |
| % Margin | -43% | -93% | -201.6% | 89.3% |
| R&D Expenses | $3 | $6 | $7 | $8 |
| G&A Expenses | $1 | $2 | $1 | $1 |
| SG&A Expenses | $2 | $3 | $4 | $3 |
| Sales & Mktg Exp. | $1 | $2 | $2 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $9 | $11 | $11 |
| Operating Income | -$5 | -$12 | -$14 | $4 |
| % Margin | -302.8% | -482.3% | -829.4% | 50.2% |
| Other Income/Exp. Net | $3 | $3 | $7 | -$5 |
| Pre-Tax Income | -$2 | -$3 | -$7 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$5 | -$7 | -$1 |
| % Margin | -134.3% | -222.2% | -412% | -14.4% |
| EPS | -0.055 | -0.13 | -0.17 | -0.025 |
| % Growth | 57.7% | 23.5% | -580% | – |
| EPS Diluted | -0.055 | -0.13 | -0.17 | -0.025 |
| Weighted Avg Shares Out | 42 | 41 | 41 | 41 |
| Weighted Avg Shares Out Dil | 42 | 42 | 41 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$2 | -$5 | -$7 | -$3 |
| % Margin | -130.6% | -216.5% | -403.4% | -36.8% |